Objective: Cardioplegic arrest (CP) and cardiopulmonary bypass (CPB) are associated with vasomotor dysfunction of coronary arterioles in patients with diabetes (DM) undergoing cardiac surgery. We hypothesized that DM may up-regulate vasopressin receptor expression and alter the contractile response of coronary arterioles to vasopressin in the setting of CP/CPB.
in arteries and arterioles. [3] [4] [5] [6] [7] [8] The mechanism resulting in this microvascular dysfunction is not completely understood, but may be related to an altered response to vasopressin. [9] [10] [11] Previous work has demonstrated that myocardial ischemia is associated with a marked increase in the contractile response of coronary microvasculature to vasopressin in the left ventricular myocardium of dogs. 11 Interestingly, large epicardial coronary arterial rings responded minimally to vasopressin, and this was not significantly altered by ischemia or reperfusion. 11 Circulating levels of vasopressin are elevated after myocardial ischemia and other stresses, 12 exemplifying the important role of vasopressin on vascular tone. Indeed, vasopressin is still used clinically as a first-line drug to increase vascular tone for maintaining systemic blood pressure after cardiac surgery 13 and to decrease mesenteric blood flow in the setting of gastrointestinal hemorrhage. 14 Few studies have examined the altered effects of vasopressin or the expression/localization of the vasopressin receptors in the human coronary microvasculature.
In fact, to our knowledge, no such studies in patients have been conducted in response to cardioplegia (CP) and cardiopulmonary bypass (CPB) in the setting of DM. We hypothesized that DM up-regulates the vasopressin receptor expression and alters the contractile response of coronary arterioles to vasopressin in the setting of CP/CPB. We first examined whether DM alters the human coronary arteriolar response to vasopressin using an in vitro microvessel preparation. We then measured the effect of DM and CP/CPB on vasopressin receptor expression/localization in coronary arterioles and myocardium using Western blotting and immunohistochemistry.
METHODS Human Subjects and Tissue Harvesting
Two sequential tissue samples were harvested from the right atrial appendage of patients undergoing a coronary artery bypass grafting procedure. The surgeons used a double purse-string technique with 3-0 polypropylene sutures on the right atrial appendage. The first specimen (before cardioplegia and cardiopulmonary bypass [pre-CP/CPB] tissue sample) was taken during initial atrial cannulation and before tightening the superior suture to secure the cannula. Then, the inferior suture remained loose throughout the procedure, enough to allow the respective atrial section to be exposed to the CP solution during cardioplegic arrest and subsequently reperfused once the aortic crossclamp was removed. The second specimen (after cardioplegia and cardiopulmonary bypass [post-CP/CPB]) was harvested after removal of crossclamp and atrial cannula. Thus, the atrium was exposed to the effects of CP/CPB and a brief period of reperfusion (approximately 5-10 minutes). The harvesting procedure has been described in detail. [4] [5] [6] 10, 15 Harvested tissue was either frozen in liquid nitrogen (immunoblotting), fixed in 10% formalin for 24 hours followed by paraffinization and sectioning into 5-mm slices (immunofluorescent staining), or stored in cold Krebs buffer (in vitro analysis).
Using hemoglobin A1C (HbA1C) and their medical history, we divided qualified patients into 2 groups: (1) patients with a normal HbA1C (<6.5) and no documented history of DM were placed in the ND group and (2) patients with a HbA1C equal to or greater than 8.5 were placed in the DM group. If a patient had a HbA1C between 6.5 and 8.5, they were excluded. Patients who experienced an aortic crossclamp time longer than 120 minutes or a CPB time longer than 180 minutes were also excluded from the study. Each group contained 8 patients. All procedures were approved by the institutional review board of Rhode Island Hospital and Brown Medical School, and informed consent was obtained from all enrolled patients as required by the institutional review board.
Cold Blood Cardioplegic Solution
Cold blood CP solution (4 C-8 C) consisted of a 4:1 mixture of oxygenated blood and hyperkalemic crystalloid CP solution (CAPS, Lanham, Md). An initial 600 to 1000 mL (introduction) of cold-blood (4 C-8 C) hyperkalemic (K þ 25 mmol/L) CP solution was delivered antegrade into the aortic root, followed by 200 to 500 mL (K þ 8 mmol/L, maintenance) of cold blood CP solution every 15 to 20 minutes.
In Vitro Analysis
Coronary arterioles (90-150 mm internal diameters) were dissected from the atrial myocardium using a 10 to 603 dissecting microscope. [4] [5] [6] 16 Microvessels were placed in the microvessel chamber and cannulated using dual glass micropipettes (40-80 mm in diameter) and then secured with 10-0 nylon monofilament sutures. Oxygenated (95% oxygen and 5% carbon dioxide) Krebs buffer solution warmed to 37 C was continuously circulated through the microvessel chamber and reservoir. The microvessels were pressurized to 40 mm Hg in a no-flow state with a burette manometer filled with a Krebs buffer solution. An inverted microscope (40 to 2003, Olympus CK2; Olympus Optical, Tokyo, Japan) connected to a video camera was used to project the vessel image onto a monitor. The internal luminal diameter was observed using an electronic dimension analyzer. Vessels were bathed in the organ chamber for at least 30 minutes before being subjected to a pharmacologic intervention. [4] [5] [6] Vasopressin (10 À8 -10 À5 M) 9, 11, 17 with or without SR 49059, a selective vasopressin 1A receptors (V1A) receptor antagonist (10 À7 M), was applied to the vessel and the response was measured.
Immunoblotting
Right atrial tissue samples harvested from 6 patients per group were dissected and cleaned of connective tissues, then placed in sodium dodecyl sulfate polyacrylamide gel electrophoresis buffer. Total protein (40 mg) was fractionated on an 8% to 16% sodium dodecyl sulfate polyacrylamide gel electrophoresis gel and then transferred to a polyvinylidene difluoride membrane (Millipore Corporation, Bedford, Mass). The membranes were incubated for 1 hour in 1:1000 dilutions of individual primary antibodies to Anti-V1A and vasopressin 1B receptor (V1B) (Abcam, Cambridge, Mass) at room temperature. The detailed methods have been described previously. [4] [5] [6] Immunoperoxidase Staining of V1A Receptors Atrial myocardial tissue sections (n ¼ 5/group) from ND and DM groups were deparaffinized in xylene and rehydrated in graded ethanol and phosphate-buffered saline (PBS) solution. The sections were incubated in 3% H 2 O 2 for 20 minutes. The section was then incubated with anti-V1A antibody (1 mg/mL) for 60 minutes at room temperature and washed with PBS. The sections were then incubated with biotinylated secondary antibody (Vector Laboratories, Burlingame, Calif). The chromogen 3,30-diaminobenzidine was then used. Atrial tissue was visualized using a Nikon E800 microscope system (Nikon, Melville, NY). Six image photos per slide were taken at the same magnification resolution (320) for optical density (intensity) analysis (Spot RT3; Diagnostic Instruments, Sterling Heights, Mich).
Immunofluorescence
Atrial tissue sections from 5 patients per group were first deparaffinized in xylene then rehydrated using graded ethanol and PBS solutions. The antigen was unmasked using sodium citrate (10 mmol/L, pH ¼ 6.0), followed by a PBS wash and blocking with 2% bovine serum albumin in PBS at room temperature for 2 hours. [4] [5] [6] After PBS wash, sections were incubated overnight with anti-V1A and V1B antibodies (each used at 1:200) (Abcam) and smooth muscle actin antibody at a temperature of 4 C. Sections were then washed in PBS and incubated with the appropriate Alexa-fluor secondary antibodies and mounted using fluorescent mounting medium (Vector Labs, Burlingame, Calif). Tissue was visualized using a Zeiss LSM510 confocal microscope system (Carl Zeiss MicroImaging, Inc, Thornwood, NY). Tissue labeled with only the actin antibody and secondary antibody served as a negative control.
Chemicals
Vasopressin and SR49059 were obtained from Sigma-Aldrich (St Louis, Mo) and dissolved in ultrapure distilled water on the day of the study.
Data Analysis
Data are presented as the mean and standard deviation. Categorical data of patient characteristics were analyzed with the Fisher exact test, and the other clinical data were analyzed with the paired Student t test. Microvascular responses are expressed as percent contraction of the baseline diameter. Microvascular data of vasopressin dose-responses were analyzed using 2-way repeated-measures analysis of variance followed by the Bonferroni multiple comparisons test. The data of immunohistochemistry and Western blot were analyzed using one-way analysis of variance followed by Bonferroni multiple comparisons test or Newman-Keuls multiple comparisons test. P values < .05 were considered significant (GraphPad Software, Inc, San Diego, Calif).
RESULTS

Patient Characteristics
Patient characteristics are listed in Table 1 . All patients (8/group) were on aspirin and b-blockers, and patients with preoperative hypertension were on antihypertensive medication. The preoperative HbA1C level averaged 8.9 AE 0.45 in patients in the DM group and 5.3 AE 0.3 in patients with the ND group.
Microvascular Contraction to Vasopressin
There were no significant differences in microvessel diameters among subgroups at baseline before vasopressin treatment (Table 2) . Vasopressin induced dose-dependent contractile responses in the microvessels of all studied groups ( Figure 1 , A and Figure 2 , A and C). There were no significant differences in the dose-dependent contractile response to vasopressin between the pre-CP/CPB-ND (before cardioplegia and cardiopulmonary bypass in patients without diabetes) and pre-CP/CPB-DM (before cardioplegia and cardiopulmonary bypass in patients with diabetes) groups (P ¼ .45, Figure 1, A) . In contrast, the dose-dependent responses to vasopressin were significantly increased after cardioplegia and cardiopulmonary bypass in patients without diabetes (post-CP/CPB-ND) and after cardioplegia and cardiopulmonary bypass in patients with diabetes (post-CP/CPB-DM) compared with its pre-CP/ CPB-ND or pre-CP/CPB-DM at tested concentrations of 10 À7 M, 10 À6 M, and 10 À5 M, respectively (*P <.05, vs pre-CP/CPB-ND, or pre-CP/CPB-DM, Figure 1, A) . This increased dose-dependent response was more pronounced in the post-CP/CPB-DM vessels than that of post-CP/ CPB-ND vessels at 10 À7 M, 10 À6 M, and 10 À5 M, respectively ( # P < .05, vs post-CP/CPB-ND, Figure 1 , A). In particular, the contractile responses of the pre-CP/CPB-ND coronary arterioles to vasopressin (10 À5 M) were significantly increased post-CP/CPB-ND (*P ¼ .0001, vs pre-CP/CPB-ND, Figure 1 , B) and post-CP/CPB-DM (*P ¼ .0001 vs pre-CP/CPB-DM, Figure 1 , B) with significant, more pronounced effects in the DM vessels than in the ND group ( # P ¼ .0001 vs post-CP/CPB-ND, Figure 1 , B). 
Effect of V1 Receptor Antagonist
Vasopressin Receptor Expression
There were no significant differences in the protein expression of the V1A receptors before CP/CPB between patients in the ND and DM groups (P ¼ .65 vs pre-CP/ CPB-ND, Figure 3 , A and C). The post-CP/CPB protein levels of V1A receptors were significantly increased compared with pre-CP/CPB values in both the ND and DM groups (*P ¼ .04 vs pre-CP/CPB-ND or *P ¼ .001 vs pre-CP/CPB-DM, Figure 3 , A and C). This increase was significantly greater in post-CP/CPB-DM than in the post-CP/CPB-ND (P ¼ .03, Figure 3 , C). There were no significant differences in the V1B receptor protein expression between the pre-CP/CPB-ND and pre-CP/CPB-DM groups (P ¼ .9, pre-CP/CPB-DM, Figure 3 , B and D) or between pre-and post-CP/CPB-ND (P ¼ .9 vs pre-CP/CPB-ND, Figure 3 , B and D). In contrast, the post-CP/CPB-DM protein levels of V1B receptors in the DM myocardium were significantly greater than those of pre-CP/CPB-DM (*P ¼ .02, Figure 3 , B and D) or post-CP/CPB-ND ( # P ¼ .01, Figure 3, D) .
Immunolocalization of V1 Receptors
Immunohistochemistry staining indicates that the V1A receptors were expressed in atrial microvessels (red arrow, Mean AE standard deviation, n ¼ 8/group. pre-CP/CPB-ND, Before cardioplegia and cardiopulmonary bypass in patients without diabetes; pre-CP/CPB-DM, before cardioplegia and cardiopulmonary bypass in patients with diabetes; post-CP/CPB-ND, after cardioplegia and cardiopulmonary bypass in patients without diabetes; post-CP/CPB-DM, after cardioplegia and cardiopulmonary bypass in patients with diabetes. Figure 4 , A) and myocardium (brown, Figure 4 , A). The intensities of V1A tended to be increased in the pre-CP/CPB-DM myocardium compared with pre-CP/CPB-ND (Figure 4 , A) but failed to reach statistical significance (P ¼ .06, Figure 4 , B). The pre-CP/CPB V1A levels also tended to be increased post-CP/CPB in both the ND (P ¼ .18 vs pre-CP/CPB-ND) and DM groups (P ¼ .34, Figure 4 , B). V1B receptors were mainly expressed in the myocardium (red, Figure 4 , C), but not in vascular smooth muscle (green, smooth muscle alpha actin staining, Figure 4 , C). The intensities of V1B pre-CP/CPB-DM (Figure 4 , D) tended to be increased in the DM myocardium but once again failed to reach statistical significance compared with pre-CP/CPB-ND (P ¼ .12, Figure 4 , D). There were no significant differences in V1B distribution between pre-and post-CP/CPB-ND in the ND group (P ¼ .3, Figure 4 , C and D). In contrast, the pre-CP/CPB-DM levels of V1B were significantly increased post-CP/ CPB-DM in the atrial myocardium of patients with DM (*P ¼ .001 vs pre-CP/CPB-DM; # P ¼ .0001 vs post-CP/ CPC-ND, Figure 4 , C and D).
DISCUSSION
In our study of the coronary arteriolar reactivity in response to vasopressin, the main findings are as follows: (1) the contractile response to vasopressin after CP/CPB in patients with the poorly controlled DM was significantly more intense than in the patients in the ND group; (2) there is a minimal contractile response to vasopressin after the addition of the V1A receptor antagonist, SR49059; (3) expression of V1A receptor protein was increased after CP/CPB for both patients in the ND and DM groups and was significantly increased in post-CP/CPB in patients in the DM group compared with patients in the ND group; (4) V1B expression was increased in DM post-CP/CPB; and (5) V1B receptor distribution was increased in atrial myocardium in patients in the DM group post-CP/CPB but not in vascular smooth muscle, which expresses few, if any, V1B receptors.
Vasopressin is produced in the posterior pituitary gland. Circulating levels of vasopressin are known to be increased at the beginning of septic shock and reduced in the later stages. 18 After cardiac surgery, circulating levels of vasopressin are either diminished or increased. 19, 20 Vasopressin may be elevated during hemorrhagic shock, hypotension, acidosis, and hypoxia. 21, 22 Although the administration of vasopressin has been advocated as a first-line drug for the treatment of postcardiac surgical vasoplegia, 20 ,22 the use of vasopressin in the setting of ischemic heart disease is associated with increased mortality. 23, 24 Thus, the use of vasopressin to support vasomotor tone in the setting of cardiac surgery has potential implications on the perfusion of the myocardium. The concentration of vasopressin we used in the current study was based on the previous in vitro vessel studies in dogs, 11 pigs, 9 and humans. 17 In a preliminary study, in the setting of CP/CPB, we observed that the change in the contractile response of human skeletal muscle arterioles to vasopressin was opposite from that observed in coronary microvasculature, but occurred at similar concentrations, suggesting that the concentrations we examined have clinical relevance.
Studies in animals and humans have shown that DM results in greater levels of plasma vasopressin 25 and decreased levels of V1 receptors in the liver and kidney of rats with type 1 DM. 26 In this study, we hypothesized that the coronary microvascular response to vasopressin would be increased after CP/CPB, and that the up-regulation of vasopressin receptors is greater in patients with DM, and this may in part be responsible for the altered coronary arteriolar contractile response to vasopressin in the setting of CP/CPB. This study suggests that the increase in coronary arteriolar contractile response in patients post-CP/CPB could be the result of increased expression of V1A receptor proteins and increased distribution of the receptors in the atrial tissue. In the patients with DM, this mechanism is augmented significantly. In the atrial myocardium from patients with DM, we also observed a significant increase in V1B receptors after CP/CPB, but this increase was not seen in the vascular smooth muscle. Our group and others have extensively studied the effect of CP/CPB on microvascular reactivity, permeability, neurocognitive decline, and other effects. [4] [5] [6] [7] [27] [28] [29] Most of the vascular effects result in a diminished response to vasoconstrictor agents such as phenylephrine, endothelin-1, and thromboxane-A 2 or endothelium-dependent vasodilator agonists such as substance P. [4] [5] [6] 8, 29 Two exceptions to this are the increased coronary contractile response observed to serotonin 10, 15 and now the response to vasopressin. The diminished contractile responses to many vasoconstrictors are due in large part to damage to the downstream contractile mechanism, including mitogen-activated protein kinase and protein kinase C, 30 altered relaxation mechanisms related to increased oxidative stress, 31 oxygen-derived free radicals, 32 neutrophilrelated mechanisms, 33 and receptor desensitization. 34 The increase in vasopressin receptor expression and responsiveness likely has to do with tissue ischemia/reperfusion and increased oxidative stress. Cell cultured experiments studying the cellular response to oxidative stress, and hypoxia, may be conducted in the future to determine the specifics mechanisms responsible for the observed increased contraction to vasopressin.
Limitations
Our study does have several possible limitations. First, we did not include patients with well-controlled DM. However, previous studies 6, 31 have shown that vascular responses in patients with controlled DM have less endothelial dysfunction than that observed in vessels from patients with poorly controlled DM. Indeed, most vascular responses in patients with well-controlled DM tend to be very similar to that observed in vessels from patients who are ND. Second, we did not examine mechanisms causing the observed effects. However, even though sample size is small, the groups were fairly well matched. Thus, any difference in response to vasopressin must have been due to DM or some factors related to it. These factors could include chronic hyperglycemia, increased oxidative stress, advanced glycosylation end products, or DM-induced dyslipidemia. It is likely that all of these factors could have contributed in some degrees to the change in vascular reactivity. Although the patients with DM in this study had received perioperative oral hypoglycemic agents and/or insulin, a previous study in dogs found a similar increased Vasopressin 1A receptor; ND, nondiabetic; DM, diabetes; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; V1B, vasopressin 1B receptor; pre-CP/ CPB-ND, before cardioplegia and cardiopulmonary bypass in patients without diabetes; post-CP/CPB-ND, after cardioplegia and cardiopulmonary bypass in patients without diabetes; pre-CP/CPB-DM, before cardioplegia and cardiopulmonary bypass in patients with diabetes; post-CP/CPB-DM, after cardioplegia and cardiopulmonary bypass in patients with diabetes.
contractile response to vasopressin. In that study, the animals did not receive either insulin or hypoglycemic medications.
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Third, we did not measure blood vasopressin concentrations during cardiac surgery. This would have possibly increased the clinical impact of the study. Fourth, this study focused on the response of atrial microcirculation. These effects on the ventricular myocardium could be clinically more significant. Unfortunately, due to the nature of the study, it would be difficult to sample ventricular myocardium of our patients undergoing coronary artery bypass surgery. However, we feel comfortable generalizing our study to the ventricular myocardium based on previous studies in animals. In canine studies in which arterial microvessels were harvested from the ventricular myocardium, the investigators observed a similar increase in reactivity of the ventricular microvasculature to vasopressin after ischemia as was observed in the atrial microvasculature in the current study.
In summary, we observed an increased coronary microvascular contractile response to vasopressin after cardiac surgery, associated with an increased expression of V1 receptors. These changes were more evident in patients with poorly controlled DM (Video 1). Thus, practitioners should be aware of the increased contractile response of coronary arterioles patients may have to vasopressin after cardiac surgery when considering administration of this drug. 22, [35] [36] [37] [38] FIGURE 4. A, Immunohistochemical image of V1A in paraffin-embedded human atrial tissue slides from patients in the ND and DM groups. Red arrows show V1A signals in the atrial microvessels. B, Densitometric analysis of signal intensities. C, Immunofluorescence staining of V1B receptors in the embedded human atrial tissue slides from patients in the ND and DM groups before and after CP/CPB. D, Densitometric analysis of signal intensities. *P<.05 versus pre-CP/CPB-DM, #P<.05 versus post-CP/CPB-ND; n ¼ 5/group, mean AE standard deviation. V1A, Vasopressin 1A receptor; V1B, vasopressin 1B receptor; pre-CP/CPB-DM, before cardioplegia and cardiopulmonary bypass in patients with diabetes; post-CP/CPB-ND, after cardioplegia and cardiopulmonary bypass in patients without diabetes; ND, nondiabetic; DM, diabetes.
